ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies

Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies A discussion interview with Peihua Lu MD from Lu Daopei Hospital in Beijing, China and Robert Chiesa MD PhD from Great Ormond Street Hospital for Children, London, UK, at the American Society of Hematology Annual Meeting in Orlando, Florida, USA ORLANDO, USA—Children and young adults whose T-cell malignancies had become refractory to all standard treatments have been rescued by means of two different chimeric antigen receptor T-cell therapies: one developed commercially in China and the other created in the laboratory of a leading children’s hospital in London by means of a new method of engineering DNA called: “base editing”.   At the 2025 American Society of Hematology annual meeting in Orlando, Florida, lead author of the Chinese study, Peihua Lu MD from Lu Daopei Hospital in Beijing and team-leader Robert Chiesa MD PhD from Great Ormond Street Hospital for Children, London, UK, met up with Audio Journal of Oncology anchor, Peter Goodwin, to discuss their pioneering early studies which seem to offer hope for patients and their families.   Audio Journal of Oncology:  Peihua Lu MD and Robert Chiesa MD PhD IN: “[GOODWIN] Welcome to….            OUT:  ……..from all of us, Good-bye ” 33:51   A discussion on ASH ABSTRACTS at the 2025 Annual Meeting: Abstract 1042: “CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) – report of clinical outcomes at the recommended phase 2 dose (RP2D)” Abstract 1041: “Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia”    

There are no comments yet.

Please log in to write the first comment.